A comparison of the second-generation Bruton tyrosine kinase (BTK) inhibitor acalabrutinib to the first-generation ibrutinib shows the former had lower rates of adverse events in a real-world setting.

suggesting potential benefits of BTK inhibitors in treating conditions such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, allergies, and asthma.

Roche has presented more data from a Phase II study of its Bruton’s tyrosine kinase (BTK) inhibitor after long-term data ...

Data presented at the 2024 Society of Hematologic Oncology (SOHO) Annual Meeting showed that irrespective of whether patients were treated with a BTK inhibitor in the first or second line, the ...

Sanofi has paused recruitment in its international phase 3 trials of BTK inhibitor tolebrutinib for multiple sclerosis, although it says studies aimed at getting US approval are on track to ...

Sanofi SA’s brain-penetrant Bruton's tyrosine kinase (BTK) inhibitor, tolebrutinib, met the primary endpoint in the phase III Hercules trial in non-relapsing secondary progressive multiple sclerosis ...

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improvements in disease ...

Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet ...

Half of patients with Richter transformation responded to the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib (Jaypirca) ...